OTCMKTS:DGNOF DIAGNOS (DGNOF) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free DGNOF Stock Alerts $0.22 -0.01 (-4.27%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.22▼$0.2350-Day Range$0.18▼$0.2552-Week Range$0.18▼$0.43Volume15,000 shsAverage Volume45,254 shsMarket Capitalization$17.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get DIAGNOS alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About DIAGNOS Stock (OTCMKTS:DGNOF)DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More DGNOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DGNOF Stock News HeadlinesMay 14, 2024 | americanbankingnews.comDIAGNOS (OTCMKTS:DGNOF) Shares Down 2.8% May 9, 2024 | globenewswire.comDIAGNOS Announces Closing of First Tranche of Private PlacementMay 6, 2024 | globenewswire.comDIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024April 16, 2024 | globenewswire.comDIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certificationApril 9, 2024 | globenewswire.comDIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11thApril 3, 2024 | globenewswire.comDIAGNOS Announces Grant of Stock OptionsApril 2, 2024 | globenewswire.comDIAGNOS Welcomes Dr. Philippe Couillard to its Board of DirectorsMarch 22, 2024 | globenewswire.comDIAGNOS Announces Closing of Second and Final Tranche of Private PlacementMarch 4, 2024 | globenewswire.comDIAGNOS Announces Grant of Stock OptionsFebruary 29, 2024 | globenewswire.comDIAGNOS Welcomes Mr. Michael Braeuel to its Board of DirectorsFebruary 27, 2024 | globenewswire.comDIAGNOS Announces Closing of First Tranche of Private PlacementFebruary 23, 2024 | globenewswire.comDiagnos Announces Variation in One Insider Ownership of Common SharesFebruary 21, 2024 | globenewswire.comDIAGNOS recognized as a Top TSX Venture Exchange CompanyDecember 8, 2023 | nytimes.comBest of 2023See More Headlines Receive DGNOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/19/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:DGNOF CUSIPN/A CIKN/A Webwww.diagnos.ca Phone(450) 678-8882FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,880,000.00 Net Margins-1,553.79% Pretax Margin-1,032.49% Return on EquityN/A Return on Assets-297.10% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.79 Sales & Book Value Annual Sales$370,000.00 Price / Sales46.40 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-11.20Miscellaneous Outstanding Shares76,650,000Free FloatN/AMarket Cap$17.17 million OptionableNot Optionable Beta0.19 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Andre LarenteCEO, President & Executive ChairmanMr. Marc-André MassueVP of Finance, CFO & SecretaryMr. Yves-Stéphane CoutureChief Operating OfficerMr. Martin BelandDirector of MarketingKey CompetitorsNextech3D.AIOTCMKTS:NEXCFReliq Health TechnologiesOTCMKTS:RQHTFVictory Square TechnologiesOTCMKTS:VSQTFVoyager DigitalOTCMKTS:VYGVFCynergisTekNYSEAMERICAN:CTEKView All Competitors DGNOF Stock Analysis - Frequently Asked Questions How have DGNOF shares performed in 2024? DIAGNOS's stock was trading at $0.3050 on January 1st, 2024. Since then, DGNOF shares have decreased by 26.6% and is now trading at $0.2240. View the best growth stocks for 2024 here. How were DIAGNOS's earnings last quarter? DIAGNOS Inc. (OTCMKTS:DGNOF) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million for the quarter. How do I buy shares of DIAGNOS? Shares of DGNOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DGNOF) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.